Skip to main content
Fanli Digital Technology Co., Ltd logo

Fanli Digital Technology Co., Ltd — Investor Relations & Filings

Ticker · 600228 ISIN · CNE000000Y78 Shanghai Stock Exchange Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 2,248 across all filing types
Latest filing 2020-12-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600228

About Fanli Digital Technology Co., Ltd

https://corp.fanli.com/

Fanli Digital Technology Co., Ltd. provides e-commerce integration and digital marketing services. The company operates a comprehensive platform that connects consumers with various online retail ecosystems through value-added services such as cash-back rewards, discount coupons, and promotional insights. Its core business model focuses on performance-based marketing, utilizing data-driven strategies to facilitate sales conversions for brand partners. Key offerings include brand promotion, user loyalty management, and targeted advertising solutions. By integrating diverse shopping channels into a single interface, the company optimizes the consumer purchasing journey and provides brands with scalable traffic acquisition tools. The platform serves as a strategic intermediary, leveraging user behavioral data to enhance marketing efficiency and provide measurable returns for merchants while delivering cost savings to a broad user base.

Recent filings

Filing Released Lang Actions
关于公司重大资产置换、发行股份及支付现金购买资产并募集配套资金暨关联交易报告书（草案）（修订稿）的修订说明公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding revisions to a draft report related to a major asset swap, share issuance, cash payment for asset purchase, and related party transactions. It references a previous report and regulatory approval from the China Securities Regulatory Commission's M&A committee. The document is short (954 characters) and primarily serves to inform about updates to a previously disclosed report rather than containing the full report itself. This fits the pattern of a Regulatory Filing (RNS) as it is a regulatory announcement about amendments to a filing, not the filing itself. It is not a full Annual Report, Capital/Financing Update, or Merger & Acquisition filing but an announcement about revisions to such a report.
2020-12-29 Chinese
关于控股股东部分股份解除质押的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the release of a portion of pledged shares by the controlling shareholder of the company. It details the number of shares released from pledge, the remaining pledged shares, and related shareholder information. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about share pledge status, which fits the category of Share Issue/Capital Change or Transaction in Own Shares. However, since it specifically concerns the release of pledged shares (a change in share pledge status), it aligns best with Transaction in Own Shares (POS). The document length is short (1113 characters), and it is a direct announcement, not a report or certification. Therefore, the appropriate classification is POS with high confidence.
2020-12-29 Chinese
江西昌九生物化工股份有限公司关于并购重组审核委员会审核意见的回复
M&A Activity Classification · 95% confidence The document is a detailed written reply from Jiangxi Changjiu Biochemical Co., Ltd. to the China Securities Regulatory Commission's Mergers and Acquisitions Review Committee regarding a major asset restructuring, share issuance for asset purchase, and related fundraising. It includes extensive disclosures about the impact of shareholder control restrictions, solutions to these issues, industry competition, customer development, and sustainable profitability of the target assets. The document references a "Restructuring Report (Revised Draft)" and contains independent financial advisor and legal opinions. The content is focused on merger and acquisition activities, specifically addressing regulatory review comments and providing supplementary disclosures related to a major asset restructuring transaction. It is not a full annual or interim financial report, earnings release, or a simple announcement. It is a substantive filing related to M&A activity and regulatory review of such transaction.
2020-12-29 Chinese
江西昌九生物化工股份有限公司重大资产置换、发行股份及支付现金购买资产并募集配套资金暨关联交易报告书（草案）（修订稿）摘要
Capital/Financing Update Classification · 95% confidence The document is titled as a "重大资产置换、发行股份及支付现金购买资产并募集配套资金暨关联交易报告书（草案）摘要" which translates to "Report on Major Asset Restructuring, Issuance of Shares and Payment of Cash to Purchase Assets and Raising Supporting Funds and Related Party Transactions (Draft) Summary." It details a major asset swap, issuance of shares, cash purchase of assets, and fundraising activities. It includes detailed transaction parties, asset valuations, share issuance pricing, and compliance with regulatory requirements. The document references the China Securities Regulatory Commission (CSRC) and Shanghai Stock Exchange rules, indicating it is a formal regulatory filing related to a major asset restructuring and capital raising. The document is lengthy (15,000 characters) and contains substantive financial and transaction details, not merely an announcement or summary. This type of document corresponds to a Capital/Financing Update (CAP) as it provides detailed information on fundraising, issuance of shares, and asset purchase transactions. It is not an Annual Report, Audit Report, or Merger & Acquisition filing per se, but a detailed report on a capital restructuring and financing transaction. Therefore, the appropriate classification is CAP with high confidence.
2020-12-29 Chinese
昌九生化关于重大资产重组交易事项获得中国证监会并购重组委审核有条件通过暨公司股票复牌的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jiangxi Changjiu Biochemical Co., Ltd. regarding the conditional approval by the China Securities Regulatory Commission's M&A Committee for a major asset swap, share issuance, cash purchase of assets, and related party transactions. It also mentions the resumption of stock trading. The document references regulatory approval and stock exchange procedures but does not contain detailed financial statements or comprehensive report data. It is a formal announcement about a financing and restructuring event, specifically related to capital and financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and it is not a full report but an announcement of approval and stock resumption.
2020-12-24 Chinese
华泰联合证券有限责任公司关于江西昌九生物化工股份有限公司重大资产置换、发行股份及支付现金购买资产并募集配套资金暨关联交易方案调整不构成重组方案重大调整的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent financial advisor's opinion on the adjustment of a major asset swap, share issuance, cash purchase of assets, and related fundraising plan by Jiangxi Changjiu Biochemical Co., Ltd. It discusses the specifics of the transaction adjustments, regulatory compliance with asset restructuring rules, and concludes that the adjustments do not constitute a major change to the restructuring plan. The document includes procedural details, board and shareholder meeting authorizations, and the independent financial advisor's verification opinion. It is not a full annual or interim financial report, earnings release, or a simple announcement. It is a standalone audit or verification report related to a specific transaction and compliance with regulatory requirements. Therefore, it fits best under Audit Report / Information (AR). The document length is 2771 characters, which is consistent with a detailed advisory or audit opinion rather than a full report or brief announcement. FY 2020
2020-12-23 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.